Corcept Therapeutics Under Investigation
Corcept Therapeutics (NASDAQ: CORT) is currently facing a serious investigation prompted by recent developments relating to its proposed treatment for hypercortisolism, commonly known as Cushing's syndrome. This investigation comes on the heels of an unfavorable report that raised concerns over its drug application, relacorilant. The situation escalated when media outlets reported that the FDA had warned Corcept multiple times against submitting their application for relacorilant, leading to a marked decline in their stock prices.
Stock Price Plummet Following Warning
On an alarming day for investors, the shares of Corcept Therapeutics dropped significantly by $7.81, reflecting a 17% drop. Just weeks earlier, on December 31, 2025, investors witnessed a staggering 50% drop following a complete response letter (CRL) from the FDA regarding relacorilant. This CRL indicated the agency’s inability to make a positive benefit-risk assessment without additional proof of the drug's effectiveness, placing investors in a precarious position.
Legal Firm Investigating Claims
The national law firm Hagens Berman has stepped in to investigate whether Corcept may have misled investors about the drug's efficacy and its potential market success. They are urging investors who have suffered significant losses to reach out for discussions about their legal rights. With concerns rising over whether Corcept may have misrepresented essential information about the drug's prospects, many investors feel apprehensive about their investments.
Positive Efficacy Claims Undermined
In prior communications, Corcept had consistently touted the effectiveness of relacorilant for patients in clinical trials, claiming that they noticed meaningful improvements. They reassured stakeholders that the new drug application was progressing and that relacorilant could set a new standard of care for hypercortisolism treatment. Management was optimistic, projecting a growth in annual revenues from $3 billion to $5 billion within three to five years, a claim that now appears to be drastically optimistic.
Market Reactions and Company Management Comments
The mood around Corcept shifted dramatically when the company disclosed the CRL and revealed significant setbacks in their efforts to secure FDA approval by the end of 2025. CEO Joseph K. Belanoff expressed disappointment regarding these developments, stating that the company had been taken by surprise.
Moreover, Hagens Berman's investigation is broadening to encompass not only potential misrepresentations regarding FDA communications but also the overstated commercial prospects for Corcept’s hypercortisolism business.
Background on Relacorilant and Market Trends
Relacorilant is an investigational therapy that has been a focal point for Corcept. Initial research indicated positive outcomes among trial participants; however, the recent revelations have led to questions regarding the integrity of these findings. The FDA's reports raise alarming concerns about liver safety, which could further complicate the approval process.
Investor Sentiment and Future Directions
Since late 2025, the market capitalization of Corcept has been drastically reduced by over $3.2 billion, prompting investors to reevaluate their positions. Many stakeholders are rightfully concerned about the company's ability to recover from this setback and deliver on previous projections.
Frequently Asked Questions
What triggered the investigation into Corcept Therapeutics?
Recent reports indicated that the FDA had warned Corcept multiple times regarding their drug application for relacorilant, raising concerns about misleading information provided to investors.
How much did Corcept's stock drop after the FDA warning?
Following the FDA's warning, Corcept's shares fell by $7.81, a 17% decline in a single trading day, after already suffering a 50% drop earlier in December.
What were Corcept's claims about relacorilant?
Corcept claimed that relacorilant had shown clinically meaningful improvements for patients in clinical trials and expected to establish itself as a new standard of care in the treatment of hypercortisolism.
What role is Hagens Berman playing in this situation?
The law firm Hagens Berman is investigating whether Corcept misled investors about the drug's efficacy and safety, as well as its communications with the FDA.
What is the future outlook for Corcept after this incident?
With significant financial losses and the ongoing investigation, the future remains uncertain for Corcept. Investors are watching closely to determine potential recovery strategies and company responses.
